ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a company targeting resistance mechanisms in cancer to improve patients' lives.
Last updated September 11, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
ORIC Pharmaceuticals, Inc. was established in 2014 with a vision of Overcoming Resistance In Cancer. The company focuses on targeting innate, acquired, and bypass resistance mechanisms in oncology, aiming to develop and commercialize innovative therapies that address cancer resistance, including by making existing therapies work better and longer. Its lead product candidate, ORIC-101, a glucocorticoid receptor antagonist, is in Phase 1b trials. The company has also initiated a Phase 3 study of rinzimetostat in combination with darolutamide in metastatic prostate cancer, and is enrolling Phase 1b studies of rinzimetostat in prostate cancer and enozertinib in NSCLC patients with EGFR exon 20 mutations.
History
ORIC Pharmaceuticals was established in 2014 with a bold vision of Overcoming Resistance In Cancer. The company focuses on targeting innate, acquired, and bypass resistance mechanisms in oncology. Its lead product candidate, ORIC-101, a glucocorticoid receptor antagonist, is in Phase 1b trials. The company has initiated a Phase 3 study of rinzimetostat in combination with darolutamide in metastatic prostate cancer patients previously treated with abiraterone, and is enrolling Phase 1b studies of rinzimetostat in prostate cancer and enozertinib in NSCLC patients with EGFR exon 20 mutations.
Products and positioning
Targeting resistance mechanisms to improve patients' lives.
Recent events
Carl L. Gordon resigns from ORIC's board[4]
Reported:
ORIC stated that Carl L. Gordon resigned from its board concurrent with Angie You's appointment.
ORIC appoints Angie You to its board[4]
Reported:
ORIC Pharmaceuticals announced the appointment of Angie You, Ph.D., to its board of directors.
ORIC Pharmaceuticals appoints Christian V. Kuhlen as General Counsel[5]
Reported:
ORIC Pharmaceuticals announced that Christian V. Kuhlen had been named General Counsel and would serve on its executive leadership team.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/oric-pharmaceuticals-inc-united-states · Editorial policy · How profiles are compiled